“This marks the first time a KEYTRUDA-based regimen has shown the ability to help certain patients with platinum-resistant ovarian cancer live longer, and the first time an immune checkpoint ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

Merck said last week its biggest tariff exposure is through Keytruda and it has enough US inventory for this year. It estimated $200 million in additional costs for the levies implemented to date.

For the breakthrough perioperative head and neck cancer indication, Keytruda is only allowed in patients with PD-L1-positive tumors. Merck & Co.’s Keytruda has become the first immunotherapy ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion last year. Keytruda may also face “ price setting ” from the ...

AACR: Merck's Keytruda prevents head and neck cancer from returning in industry-first win By Angus Liu Apr 28, 2025 1:28pm Merck & Co. Keytruda head and neck cancer PD-1/L1 ...

Mural Oncology (MURA) announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda – pembrolizumab – versus investigator’s ...

CHICAGO — A treatment that combines two different types of cancer-fighting medicines — Gilead Sciences’ Trodelvy with Merck’s Keytruda — reduced the risk of tumor progression by more ...